astrzeneca goserelin goserelin 10.8mg (as acetate) implant syringe
astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.
zoladex
astrazeneca uk limited - goserelin acetate - implant - 3.6 base milligrams - goserelin
zoladex la
astrazeneca uk limited - goserelin acetate - implant - 10.8 base milligrams - goserelin
zoladex 3.6mg implant
astrazeneca uk limited - goserelin - implant - goserelin - endocrine therapy
zoladex la 10.8mg implant
astrazeneca uk limited - goserelin - implant - goserelin - endocrine therapy
esmya
pharmacy retailing (nz) ltd t/a healthcare logistics - ulipristal acetate 5mg - tablet - 5 mg - active: ulipristal acetate 5mg excipient: croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose purified talc - ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
eligard leuprorelin acetate 30mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
eligard leuprorelin acetate 22.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
eligard leuprorelin acetate 7.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1
zoladex 3.6mg implant
astrazeneca ab se-151 85, södertälje, sweden - goserelin - implant - goserelin 3.6 mg - endocrine therapy